ClinConnect ClinConnect Logo
Search / Trial NCT06481176

Blood Changes After Exercise in Restless Legs Syndrome

Launched by STANFORD UNIVERSITY · Jun 27, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Exercise Proteomics

ClinConnect Summary

This clinical trial is studying how exercise affects the blood in people with Restless Legs Syndrome (RLS), a condition that causes uncomfortable sensations in the legs and an urge to move them. Researchers want to find out if exercising regularly changes certain proteins in the blood and how a single exercise session can impact these proteins. Participants in the study will be split into two groups: one group will exercise, while the other will not, for 12 weeks. Before and after the exercise, participants will take an exercise test and provide blood samples to help gather this information.

To join the study, you need to be at least 18 years old, have a diagnosis of moderate-to-severe RLS, and currently be inactive (not exercising regularly). You should also be able to walk without assistance. However, if you have other medical conditions that could mimic RLS or make exercise risky, you may not be eligible. If you decide to participate, you can expect to engage in an exercise program and help researchers learn more about RLS, which could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age 18 years or older;
  • diagnosis of RLS;
  • presence of moderate-to-severe RLS (IRLS score\>15);
  • currently untreated RLS;
  • being non-active defined as not engaging in regular activity (30 minutes accumulated per day) on more than 2 days of the week during the previous six months;
  • ability to walk without assistance (does not use a cane/walker/wheelchair for mobility;
  • willing to complete outcome measures and complete the exercise program
  • Exclusion Criteria:
  • present with a condition that can mimic RLS or cause secondary RLS (e.g., iron deficiency anemia, radiculopathy, peripheral edema, peripheral neuropathy, diabetes);
  • are at moderate or high risk for undertaking strenuous or maximal exercise

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

Stanford, California, United States

Patients applied

0 patients applied

Trial Officials

Emmanuel Mignot, MD, PhD

Principal Investigator

Stanford University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported